Business

Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS

The Company honors one of its largest providers for helping patients overcome depression with NeuroStar Advanced Therapy for Mental Health MALVERN, Pa., Oct.

articleNeuronetics, Inc.October 26, 20213/company/neuronetics-inc/news/neuronetics-celebrates-235000-treatment-milestone-for-success-tms
Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS

About this update from Neuronetics, Inc.

[{"type":"text","content":"The Company honors one of its largest providers for helping patients overcome depression with NeuroStar Advanced Therapy for Mental Health\nMALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced a leading provider, Success TMS, has reached an impressive milestone delivering over 235,000 NeuroStar transcranial magnetic stimulation (TMS) treatments to patients across the U.S, in just 3 short years. Founded by Jonathan Michel in 2018 after the loss of his sister to suicide, Success TMS opened its flagship location in South Florida in 2018. The practice has since expanded to over 30 treatment centers in six states, providing more than 235,000 treatments to patients with Major Depressive Disorder (MDD) using NeuroStar Advanced Therapy – a non-drug and non-invasive treatment that stimulates areas of the brain that are underactive in depression.1,2 This treatment milestone, achieved in less than three years, has put the practice closer to its goal of providing one million NeuroStar treatments and furthered its mission to rid the world of depression, a disease that impacts more than 17.3 million American adults.3 “We are delighted to celebrate Success TMS for achieving such a remarkable milestone. It is because of partners like Success TMS that those struggling to find relief from depression with antidepressants have access to innovative treatments like NeuroStar,” said Keith J. Sullivan, President and CEO of Neuronetics. “Our companies share a vision of transforming lives and helping patients overcome their depression with help from NeuroStar. The entire Success TMS team is incredibly dedicated to serving their communities and we look forward to their continued partnership and success.” Today, Success TMS is one of the leading TMS therapy providers in the U.S. and is focused on providing compassionate care and quality clinical expertise to patients for achieving long-term remission. Even as depression rates soar due to the COVID-19 pandemic,4 Success TMS continues to offer best-in-class treatment to those in need and has seen demand for its mental health services increase by 20 percent over the past year. “To make ...

More updates from Neuronetics, Inc.